^
    1m
    TRANSPIRE: A Study to Learn About the Effects of Felzartamab Infusions on Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation (clinicaltrials.gov)
    P2, N=81, Not yet recruiting, Biogen
    New P2 trial
    |
    felzartamab (MOR202)
    6ms
    PROMINENT: A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) (clinicaltrials.gov)
    P3, N=180, Recruiting, Biogen | Not yet recruiting --> Recruiting
    Enrollment open
    |
    felzartamab (MOR202)
    7ms
    PREVAIL: A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) (clinicaltrials.gov)
    P3, N=454, Recruiting, Biogen | Not yet recruiting --> Recruiting
    Enrollment open
    |
    felzartamab (MOR202)
    7ms
    PROMINENT: A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) (clinicaltrials.gov)
    P3, N=180, Not yet recruiting, Biogen
    New P3 trial
    |
    felzartamab (MOR202)
    7ms
    TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=113, Completed, TJ Biopharma Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    felzartamab (MOR202)
    8ms
    PREVAIL: A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) (clinicaltrials.gov)
    P3, N=454, Not yet recruiting, Biogen
    New P3 trial
    |
    felzartamab (MOR202)
    9ms
    MONET: MOR202 for Refractory MN (clinicaltrials.gov)
    P2, N=10, Completed, Mario Negri Institute for Pharmacological Research | Active, not recruiting --> Completed
    Trial completion
    |
    felzartamab (MOR202)
    10ms
    A Study of Felzartamab in Participants With Lupus Nephritis (clinicaltrials.gov)
    P1/2, N=20, Recruiting, HI-Bio, A Biogen Company | Phase classification: P1 --> P1/2
    Phase classification
    |
    felzartamab (MOR202)
    12ms
    TRANSCEND: A Trial of Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR) (clinicaltrials.gov)
    P3, N=120, Recruiting, HI-Bio, A Biogen Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    felzartamab (MOR202)
    1year
    TRANSCEND: A Trial of Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR) (clinicaltrials.gov)
    P3, N=120, Not yet recruiting, HI-Bio, A Biogen Company
    New P3 trial
    |
    felzartamab (MOR202)
    1year
    A Study of Felzartamab in Participants With Lupus Nephritis (clinicaltrials.gov)
    P1, N=20, Recruiting, HI-Bio | Trial completion date: May 2025 --> Jun 2026 | Trial primary completion date: May 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    felzartamab (MOR202)
    1year
    Study of Felzartamab in Healthy Adult Subjects (clinicaltrials.gov)
    P1, N=24, Completed, TJ Biopharma Co., Ltd. | Recruiting --> Completed | N=60 --> 24 | Trial completion date: Dec 2024 --> Aug 2024 | Trial primary completion date: Dec 2024 --> Aug 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    felzartamab (MOR202)